These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33868046)

  • 1. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.
    Sneller MH; de Boer N; Everaars S; Schuurmans M; Guloksuz S; Cahn W; Luykx JJ
    Front Psychiatry; 2021; 12():625935. PubMed ID: 33868046
    [No Abstract]   [Full Text] [Related]  

  • 2. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.
    De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R
    Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.
    Chadda RK; Ramshankar P; Deb KS; Sood M
    J Pharmacol Pharmacother; 2013 Jul; 4(3):176-86. PubMed ID: 23960422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.
    Vancampfort D; Stubbs B; Mitchell AJ; De Hert M; Wampers M; Ward PB; Rosenbaum S; Correll CU
    World Psychiatry; 2015 Oct; 14(3):339-47. PubMed ID: 26407790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics.
    Fang X; Wang Y; Chen Y; Ren J; Zhang C
    Neuropsychiatr Dis Treat; 2019; 15():2161-2170. PubMed ID: 31534339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome.
    Kornetova EG; Kornetov AN; Mednova IA; Dubrovskaya VV; Boiko AS; Bokhan NA; Loonen AJM; Ivanova SA
    Front Psychiatry; 2019; 10():803. PubMed ID: 31736812
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of metabolic syndrome with schizophrenia.
    Bajaj S; Varma A; Srivastava A; Verma AK
    Indian J Endocrinol Metab; 2013 Sep; 17(5):890-5. PubMed ID: 24083172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics.
    Jeong SH; Lee NY; Kim SH; Chung IW; Youn T; Kang UG; Ahn YM; You HY; Kim YS
    Psychiatry Investig; 2018 Jun; 15(6):628-637. PubMed ID: 29940717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
    Zuddas A; Zanni R; Usala T
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: artificial neural network and logistic regression models.
    Lin CC; Bai YM; Chen JY; Hwang TJ; Chen TT; Chiu HW; Li YC
    J Clin Psychiatry; 2010 Mar; 71(3):225-34. PubMed ID: 19814949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics.
    Ventriglio A; Baldessarini RJ; Vitrani G; Bonfitto I; Cecere AC; Rinaldi A; Petito A; Bellomo A
    Front Psychiatry; 2018; 9():744. PubMed ID: 30700975
    [No Abstract]   [Full Text] [Related]  

  • 13. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.
    Bai YM; Chen TT; Liou YJ; Hong CJ; Tsai SJ
    Schizophr Res; 2011 Feb; 125(2-3):179-86. PubMed ID: 21185157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
    Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
    Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.
    Ferrara M; Umlauf A; Sanders C; Meyer JM; Allen McCutchan J; Duarte N; Hampton Atkinson J; Grant I; Ellis RJ;
    Psychiatry Res; 2014 Aug; 218(1-2):201-8. PubMed ID: 24794030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
    Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia.
    Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C
    Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia.
    Vuksan-Cusa B; Sagud M; Jakovljevic M; Peles AM; Jaksic N; Mihaljevic S; Zivkovic M; Mikulic SK; Jevtovic S
    Nord J Psychiatry; 2013 Oct; 67(5):320-5. PubMed ID: 23228159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.